Highlights
- 1Journal of clinical gastroenterology · 2022
- 2
- 3
Publications
136 publications
Funding
6 grants
Active
2 grants- Sub-PIUCSF 230837-01Pregnancy in Inflammatory Bowel Disease And Neonatal Outcomes (PIANO)The Leona M. and Harry B. Helmsley Charitable Trust · 2022–2028 · via University of California, San Francisco
- Co-IBP 231752-01Molecular and clinical characterization of IBD patients naive or refractory to standard of care over timeBoehringer Ingelheim Pharmaceuticals, Inc. (Germany) · 2023–2028BioPharma Alliance
Completed grants (4)
- Sub-PIU01DK062431-20IBD Gene Mapping by Clinical and Population SubsetNational Institute of Diabetes and Digestive and Kidney Diseases · 2012–2022 · via Rutgers, The State University of New Jersey – New Brunswick· 2 renewals
- Sub-PIUCSF 201703-01Pregnancy and Inflammatory Bowel Disease And Neonatal Outcomes Registry: Long-term Outcomes of In-Utero Biologic ExposureCrohn's and Colitis Foundation of America · 2019–2022 · via University of California, San Francisco
- Sub-PIUPEnn 183792-01Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients with Crohn's DiseaseCrohn's and Colitis Foundation of America · 2017–2020 · via University of PennsylvaniaNo publications yet
- Sub-PIU19AI056363-10 EWMechanisms of B Cell Responses in Autoimmune DiseaseNational Institute of Allergy and Infectious Diseases · 2013–2015 · via Duke University
Clinical research
13 studies
Active
6 studies- PINCT07184944A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · Sanofi S.A. · OPEN TO ACCRUAL (as of 2026)Crohn's Disease
- PINCT07185009A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPHASE3 · Sanofi S.A. · OPEN TO ACCRUAL (as of 2026)Ulcerative Colitis
- PINCT07196748A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative ColitisPHASE3 · Janssen Research & Development, LLC · OPEN TO ACCRUAL (as of 2026)Colitis, Ulcerative
- PINCT07196722A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseasePHASE2; PHASE3 · Janssen Research & Development, LLC · OPEN TO ACCRUAL (as of 2026)Crohn Disease
- PINCT07184996A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis.PHASE3 · Sanofi S.A. · OPEN TO ACCRUAL (as of 2026)Ulcerative Colitis
- PINCT07184931A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · Sanofi S.A. · OPEN TO ACCRUAL (as of 2026)Crohn's Disease
Completed & closed trials (7)
- PINCT05242484A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisPHASE2 · Janssen Research & Development, LLC · IRB STUDY CLOSURE (as of 2026)Colitis, Ulcerative
- PINCT06257875A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative ColitisPHASE2 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2026)Ulcerative Colitis
- PINCT05369832A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical PracticePHASE4 · Bristol-Myers Squibb Company · IRB STUDY CLOSURE (as of 2025)Colitis, Ulcerative
- PINCT03466411A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseasePHASE2; PHASE3 · Janssen Research & Development, LLC · IRB STUDY CLOSURE (as of 2024)Crohn's Disease
- PINCT05242471A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseasePHASE2 · Janssen Research & Development, LLC · CLOSED TO ACCRUAL (as of 2024)Crohn's Disease
- PINCT04090411A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative ColitisPHASE2 · Pfizer, Inc. · IRB STUDY CLOSURE (as of 2023)Moderate to Severe Ulcerative Colitis
- PINCT03283085A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)PHASE3 · Shire Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2020)Crohn's Disease; Ulcerative Colitis
News mentions
1 mentionView all WCM news ↗
- Antifungal Therapy Shows Potential for IBD Patients with Candida OvergrowthSeptember 1, 2026
A commonly used systemic antifungal medication may help reduce symptoms in a subset of patients with inflammatory bowel disease (IBD) by restoring a healthier gut microbiome, according to a preliminary study by Weill Cornell Medicine investigators.
Media highlights
2 clips
- Antifungal Therapy Shows Potential For IBD Patients With Candida Overgrowth: StudyMedical Dialogues · September 3, 2026
- Antifungal Drug May Ease IBD Disease ActivityLabRoots · September 2, 2026
Mentoring
2 menteesAll publications with mentees →
- JGJonathan GalatiMD mentee · Class of 2020
External relationships
Advisory/Scientific Board Member
AbbVie Inc. · Johnson & Johnson
Speaker/Lecturer
AbbVie Inc. · Johnson & Johnson
Other
AbbVie Inc. · Johnson & Johnson